

**FORWARDHEALTH
PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL)
FOR MULTIPLE SCLEROSIS (MS) AGENTS, IMMUNOMODULATORS
COMPLETION INSTRUCTIONS**

ForwardHealth requires certain information to enable the programs to authorize and pay for medical services provided to eligible members.

Members of ForwardHealth are required to give providers full, correct, and truthful information for the submission of correct and complete claims for reimbursement. Per Wis. Admin. Code § DHS 104.02(4), this information should include, but is not limited to, information concerning enrollment status, accurate name, address, and member ID number.

Under Wis. Stat. § 49.45(4), personally identifiable information about program applicants and members is confidential and is used for purposes directly related to ForwardHealth administration such as determining eligibility of the applicant, processing prior authorization (PA) requests, or processing provider claims for reimbursement. Failure to supply the information requested by the form may result in denial of PA or payment for the services.

The use of this form is mandatory when requesting a PA for certain drugs. If necessary, attach additional pages if more space is needed. Refer to the applicable service-specific publications for service restrictions and additional documentation requirements. Provide enough information for ForwardHealth to make a determination about the request.

INSTRUCTIONS

Prescribers are required to complete and sign the Prior Authorization/Preferred Drug List (PA/PDL) for Multiple Sclerosis (MS) Agents, Immunomodulators form, F-00805. Pharmacy providers are required to use the PA/PDL for MS Agents, Immunomodulators form to request PA for non-preferred immunomodulators by submitting a PA request on the ForwardHealth Portal, by fax, or by mail. Prescribers and pharmacy providers are required to retain a completed copy of the form.

Providers may submit PA requests on a PA/PDL form in one of the following ways:

- 1) For requests submitted on the ForwardHealth Portal, pharmacy providers may access www.forwardhealth.wi.gov/.
- 2) For PA requests by fax, pharmacy providers should submit a Prior Authorization Request Form (PA/RF), F-11018, and the appropriate PA/PDL form to ForwardHealth at 608-221-8616.
- 3) For PA requests by mail, pharmacy providers should submit a PA/RF and the appropriate PA/PDL form to the following address:

ForwardHealth
Prior Authorization
Ste 88
313 Blettner Blvd
Madison WI 53784

The provision of services that are greater than or significantly different from those authorized may result in nonpayment of the billing claim(s).

SECTION I – MEMBER INFORMATION

Element 1 – Name – Member

Enter the member's last name, first name, and middle initial. Use Wisconsin's Enrollment Verification System (EVS) to obtain the correct spelling of the member's name. If the name or spelling of the name on the ForwardHealth ID card and the EVS do not match, use the spelling from the EVS.

Element 2 – Member ID Number

Enter the member ID. Do not enter any other numbers or letters. Use the ForwardHealth card or the EVS to obtain the correct member ID.

Element 3 – Date of Birth – Member

Enter the member's date of birth in MM/DD/CCYY format.

SECTION II – PRESCRIPTION INFORMATION

Element 4 – Drug Name

Enter the name of the drug.

Element 5 – Drug Strength

Enter the strength of the drug listed in Element 4.

Element 6 – Date Prescription Written

Enter the date the prescription was written.

Element 7 – Refills

Enter the number of refills.

Element 8 – Directions for Use

Enter the directions for use of the drug.

Element 9 – Name – Prescriber

Enter the name of the prescriber.

Element 10 – National Provider Identifier – Prescriber

Enter the 10-digit National Provider Identifier of the prescriber.

Element 11 – Address – Prescriber

Enter the address (street, city, state, and ZIP+4 code) of the prescriber.

Element 12 – Telephone Number – Prescriber

Enter the telephone number, including area code, of the prescriber.

SECTION III – CLINICAL INFORMATION

Prescribers are required to complete the appropriate sections before signing and dating the PA/PDL for MS Agents, Immunomodulators form.

Element 13 – Diagnosis Code and Description

Enter the appropriate and most-specific *International Classification of Diseases* (ICD) diagnosis code and description most relevant to the drug requested. The ICD diagnosis code must correspond with the ICD description.

Element 14

Indicate the drug name, daily dose, and start date of the member's current MS immunomodulator therapy. Check "None" if appropriate.

Element 15

Indicate the drug name, daily dose, dates taken, and the reason(s) for discontinuation for the member's previous MS immunomodulator therapy. Check "None" if appropriate.

SECTION IV – CLINICAL INFORMATION FOR NON-PREFERRED ORAL MS IMMUNOMODULATORS

Element 16

Provide detailed documentation in the spaces provided regarding why the member is unable to take or has previously discontinued both Aubagio® treatment and Gilenya® treatment. Medical records must be provided to support the need for a non-preferred oral agent. The following will **not** be considered as criteria to support the need for a non-preferred oral agent:

- Non-adherence to previous MS treatment.
- Member or prescriber preference for the use of a non-preferred oral agent.

SECTION V – CLINICAL INFORMATION FOR MS INTERFERONS

Element 17

Provide detailed documentation in the spaces provided regarding why the member is unable to take or has previously discontinued **at least two** preferred MS interferon treatments. Medical records must be provided to support the need for a non-preferred MS interferon. The following will **not** be considered as criteria to support the need for a non-preferred MS interferon:

- Non-adherence to previous MS treatment.
- Member or prescriber preference for the use of a non-preferred MS interferon.
- Member or prescriber preference for a less-frequent dosing schedule.

SECTION VI – CLINICAL INFORMATION FOR ZINBRYTA®

Element 18

Provide detailed documentation in the spaces provided for regarding why the member has previously discontinued a preferred agent from at least two of either Aubagio®, Gilenya®, preferred MS Interferons, or Copaxone®. Medical records must be provided to support the need for Zinbryta®. the following will **not** be considered as criteria to support the need for Zinbryta®:

- Non-adherence to previous MS treatment
- Member or prescriber preference for the use of Zinbryta®
- Member or prescriber preference for a less frequent dosing schedule

SECTION VII – CLINICAL INFORMATION FOR GLATOPA®

Element 19

Provide detailed clinical justification in the space provided for prescribing Glatopa® instead of the preferred agents, Copaxone® 20 mg and Copaxone® 40 mg. This clinical information must document why the member cannot use Copaxone® 20 mg and Copaxone® 40 mg, including why it is medically necessary that the member receive Glatopa® instead of Copaxone® 20 mg and Copaxone® 40 mg.

SECTION VIII – AUTHORIZED SIGNATURE

Element 20 – Signature – Prescriber

The prescriber is required to complete and sign this form.

Element 21 – Date Signed

Enter the month, day, and year the form was signed in MM/DD/CCYY format.

SECTION IX – ADDITIONAL INFORMATION

Element 22

Include any additional information in the space provided. Additional diagnostic and clinical information explaining the need for the drug requested may also be included.